E 6011

Drug Profile

E 6011

Alternative Names: E6011; KANAb001

Latest Information Update: 17 Feb 2017

Price : $50

At a glance

  • Originator KAN Research Institute
  • Developer EA Pharma; Eisai Co Ltd
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Chemokine CX3CL1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary biliary cirrhosis; Rheumatoid arthritis
  • Phase I/II Crohn's disease

Most Recent Events

  • 02 Feb 2017 Phase-II clinical trials in Primary biliary cirrhosis in Japan (IV) (Eisai and EA Pharma pipelines, February 2017) (JapicCTI173515)
  • 11 Nov 2016 Pharmacodynamics data from a preclinical study in Rheumatoid arthritis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals (ACR/ARHP - 2016)
  • 01 Nov 2016 Phase-II clinical trials in Rheumatoid arthritis (Adjunctive treatment) in Japan (SC) (Eisai pipeline, November 2016; NCT02960438)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top